Treatment of severe covid-19 with interleukin 6 receptor inhibition

Treatment of severe covid-19 with interleukin 6 receptor inhibition

Saved in:

Bibliographic Details
Main Authors:	Stephen Burgess, Dipender Gill, Skanda Rajasundaram
Format:	Article
Language:	English
Published:	BMJ Publishing Group 2022-12-01
Series:	BMJ Medicine
Online Access:	https://bmjmedicine.bmj.com/content/1/1/e000144.full
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

The cardiovascular effects of interleukin-6 inhibition in patients with severe coronavirus-19 infection
by: Michael S Binder, et al.
Published: (2025-04-01)

Interleukin 6 receptor inhibitors in the treatment of rheumatoid arthritis during the COVID-19 pandemic, Moscow experience
by: A. I. Zagrebneva, et al.
Published: (2022-12-01)

The evolution of mendelian randomization for investigating drug effects.
by: Dipender Gill, et al.
Published: (2022-02-01)

Evaluation of Interleukin-6 and its Association with the Severity of Disease in COVID-19 Patients
by: Sudhir Bhandari, et al.
Published: (2020-07-01)

Long-term increase in soluble interleukin-6 receptor levels in convalescents after mild COVID-19 infection
by: Juliane Lokau, et al.
Published: (2025-01-01)

Experience with the use of recombinant humanized monoclonal antibodies to the human receptor for interleukin-6 in patients with CoVID-19
by: D. А. Gusev, et al.
Published: (2020-08-01)

Interleukin-6 and other cytokine blockade in COVID-19 hyperinflammation
by: Latika Gupta, et al.
Published: (2020-01-01)

Editorial comments to “Increased interleukin‐6 levels are associated with atrioventricular conduction delay in severe COVID‐19 patients”
by: Bonpei Takase, et al.
Published: (2024-10-01)

New areas of the pharmacotherapy of rheumatic diseases are inhibition of interleukin-6 and interleukin-17
by: Evgeny Lvovich Nasonov
Published: (2013-10-01)

Reassessing the validity of using weighted linear models to implement multi-generational GWAS-by-subtraction: a response to Evans et al.
by: Benjamin Woolf, et al.
Published: (2025-06-01)

The Association of Polymorphisms in Interleukin-6 (IL-6), Interleukin-10 (IL-10), IL-6 Receptor, and IL-10 Receptor Genes with the Risk of Pediatric Inflammatory Bowel Disease
by: Krawiec P, et al.
Published: (2025-06-01)

IMMUNOPATHOLOGY AND IMMUNOPHARMACOTHERAPY OF CORONAVIRUS DISEASE 2019 (COVID-19): FOCUS ON INTERLEUKIN 6
by: E. L. Nasonov
Published: (2020-06-01)

Generation of Soluble Interleukin-11 and Interleukin-6 Receptors: A Crucial Function for Proteases during Inflammation
by: Juliane Lokau, et al.
Published: (2016-01-01)

Management of patients with rheumatoid arthritis in real clinical practice: Switching from interleukin 6 receptor inhibitors to interleukin 6 inhibitor (olokizumab)
by: A. A. Baranov, et al.
Published: (2023-06-01)

Prognostic significance of serum interleukin-6 in severe/critical COVID-19 patients treated with tocilizumab: a detailed observational study analysis
by: Panpan Liang, et al.
Published: (2024-11-01)

Investigation the concentration of interleukin-6, interleukin-10, and vitamin D in diabetic patients with covid-19 hospitalized in the intensive care unit
by: Farnaz Seifi-Skishahr, et al.
Published: (2023-03-01)

EXPERIENCE WITH TOCILIZUMAB, AN INTERLEUKIN 6 INHIBITOR, USED FOR THE TREATMENT OF GIANT CELL ARTERITIS WITH SEVERE COMORBIDITY
by: T. V. Beketova, et al.
Published: (2018-05-01)

Interleukin 6 inhibition: new possibilities of pharmacotherapy for immunoinflammatory rheumatic diseases
by: E L Nasonov, et al.
Published: (2013-11-01)

The prospects of interleukin-6 inhibition in rheumatoid arthritis: Olokizumab (novel monoclonal antibodies to IL-6)
by: E. L. Nasonov, et al.
Published: (2022-11-01)

The role of interleukin‐6 in monitoring severe case of coronavirus disease 2019
by: Tao Liu, et al.
Published: (2020-06-01)

Noise-augmented directional clustering of genetic association data identifies distinct mechanisms underlying obesity.
by: Andrew J Grant, et al.
Published: (2022-01-01)

INHIBITION OF INTERLEUKIN 6 IN IMMUNE INFLAMMATORY RHEUMATIC DISEASES: ACHIEVEMENTS, PROSPECTS, AND HOPES
by: E. L. Nasonov, et al.
Published: (2018-01-01)

Switching from interleukin-6 receptor inhibitors to the direct interleukin-6 inhibitor olokizumab in patients with rheumatoid arthritis: efficacy and safety during one year of therapy
by: P. A. Shesternya, et al.
Published: (2024-10-01)

The Important Role of Interleukin-2 in COVID-19
by: Leila Ghanbari Naeini, et al.
Published: (2023-01-01)

A comprehensive review and meta-analysis of the relationships between interleukin-7 levels and COVID-19 severity
by: Michal MATUSZEWSKI, et al.
Published: (2023-03-01)

Time- and dose-dependent inhibition of neutrophil extracellular trap formation by blocking of the interleukin-1 receptor
by: Hannah Wadehn, et al.
Published: (2021-12-01)

Effect of soluble interleukin-6 receptor α and interleukin-6 secreted by polymorphonuclear leukocytes on tumor necrosis factor-α expression and its production by peripheral blood mononuclear cells
by: E. Jablonska
Published: (2002-01-01)

Response to Treatment with an Anti-Interleukin-6 Receptor Antibody (Tocilizumab) in a Patient with Hemophagocytic Syndrome Secondary to Immune Checkpoint Inhibitors
by: Alejandro Olivares-Hernández, et al.
Published: (2021-01-01)

B-lymphocyte subpopulations in patients with rheumatoid arthritis and the effect of an interleukin-6 receptor inhibitor on them.
by: E. V. Gerasimova, et al.
Published: (2019-01-01)

Determination of Serum Levels of Interleukin-6 and the Trace Element Zinc According to the Clinical Status of Patients With COVID-19
by: Andrea Roman-Pimentel, et al.
Published: (2025-01-01)

Intrathecal interleukin-6 levels are associated with progressive disease and clinical severity in multiple sclerosis
by: Justine Itorralba, et al.
Published: (2025-04-01)

The interleukin-1 receptor antagonist influences interleukin-1 effects in rat and mouse
by: P. Bjrök, et al.
Published: (1992-01-01)

Successful Treatment of a Patient with Giant Cell Vasculitis (Horton Arteritis) with Tocilizumab a Humanized Anti-Interleukin-6 Receptor Antibody
by: Alfredomaria Lurati, et al.
Published: (2012-01-01)

Tumor Differentiation is Correlated with Estrogen Receptor Beta (ERβ) Expression but Not with Interleukin-6 (IL-6) Expression in Colorectal Carcinoma
by: Imelda Theodora, et al.
Published: (2024-10-01)

Inflammatory cytokines, soluble interleukin-6 receptors, and fragmented cytokeratin-18 as indicators of non-alcoholic steatohepatitis
by: Anastasia A. Shipovskaya, et al.
Published: (2025-01-01)

Role of Toll-like receptors polymorphisms in the development of extremely severe COVID-19
by: Lyudmila A. Ashchina, et al.
Published: (2025-04-01)

Translational Pharmacokinetics of Icotrokinra, a Targeted Oral Peptide that Selectively Blocks Interleukin-23 Receptor and Inhibits Signaling
by: Beverly Knight, et al.
Published: (2025-07-01)

Independent role of interleukin interleukin-6 and interleukin-8 in the etiology of transfusion reactions to platelet concentrates in children
by: Šerbić-Nonković Olivera, et al.
Published: (2018-01-01)

Interleukin 18 in Immune-mediated rheumatic diseases and COVID-19
by: E. L. Nasonov, et al.
Published: (2022-05-01)

Soluble interleukin-2 receptors in ulcerative colitis
by: O. H. Nielsen, et al.
Published: (1993-01-01)